Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 13.29B | 13.03B | 12.59B | 12.33B | 11.70B | 10.83B |
Gross Profit | 5.93B | 5.70B | 5.48B | 5.37B | 5.26B | 5.08B |
EBITDA | 1.49B | 1.73B | 1.50B | 1.47B | 1.43B | 1.40B |
Net Income | 703.04M | 840.90M | 154.02M | 482.21M | 660.41M | 659.52M |
Balance Sheet | ||||||
Total Assets | 18.23B | 20.05B | 19.26B | 18.87B | 18.08B | 17.10B |
Cash, Cash Equivalents and Short-Term Investments | 4.71B | 6.32B | 4.39B | 4.31B | 4.36B | 3.97B |
Total Debt | 42.96M | 800.00M | 800.00M | 800.00M | 800.00M | 892.40M |
Total Liabilities | 2.93B | 4.30B | 4.31B | 4.14B | 3.86B | 3.87B |
Stockholders Equity | 15.31B | 15.75B | 14.94B | 14.72B | 14.22B | 13.23B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 1.77B | 246.98M | 101.75M | 629.58M | 839.00M |
Operating Cash Flow | 0.00 | 2.25B | 698.84M | 461.34M | 1.25B | 1.25B |
Investing Cash Flow | 0.00 | 270.62M | -363.61M | 38.01M | -585.01M | -704.31M |
Financing Cash Flow | 0.00 | -877.65M | -362.19M | -355.59M | -442.52M | -845.03M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | ¥9.18B | 12.30 | ― | 3.67% | 3.38% | 88.65% | |
78 Outperform | ¥8.89B | 11.49 | ― | 2.00% | 9.07% | 43.42% | |
77 Outperform | ¥13.11B | 10.45 | ― | 2.98% | 12.36% | 38.55% | |
74 Outperform | ¥16.35B | 15.69 | ― | 3.54% | -8.07% | -38.21% | |
56 Neutral | ¥13.40B | 10.23 | ― | 2.93% | 4.84% | -148.94% | |
54 Neutral | ¥33.85B | ― | -49.32% | ― | 45.67% | 29.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Create Medic Co., Ltd. reported its consolidated financial results for the first half of 2025, showing a 4.2% increase in net sales compared to the previous year. Despite a significant rise in operating and ordinary profits, the profit attributable to owners of the parent decreased by 25%. The company maintained a strong capital adequacy ratio of 84.0% and announced a forecasted annual dividend of 37 yen per share. These results indicate a mixed performance, with growth in sales and profits but a decline in net income, which may affect stakeholder confidence.